The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranov, Maksim V., Bianchi, Frans, van den Bogaart, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824419/
https://www.ncbi.nlm.nih.gov/pubmed/33375410
http://dx.doi.org/10.3390/cells10010030
_version_ 1783640072508145664
author Baranov, Maksim V.
Bianchi, Frans
van den Bogaart, Geert
author_facet Baranov, Maksim V.
Bianchi, Frans
van den Bogaart, Geert
author_sort Baranov, Maksim V.
collection PubMed
description The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.
format Online
Article
Text
id pubmed-7824419
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78244192021-01-24 The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19 Baranov, Maksim V. Bianchi, Frans van den Bogaart, Geert Cells Opinion The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod. MDPI 2020-12-27 /pmc/articles/PMC7824419/ /pubmed/33375410 http://dx.doi.org/10.3390/cells10010030 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Baranov, Maksim V.
Bianchi, Frans
van den Bogaart, Geert
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title_full The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title_fullStr The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title_full_unstemmed The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title_short The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
title_sort pikfyve inhibitor apilimod: a double-edged sword against covid-19
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824419/
https://www.ncbi.nlm.nih.gov/pubmed/33375410
http://dx.doi.org/10.3390/cells10010030
work_keys_str_mv AT baranovmaksimv thepikfyveinhibitorapilimodadoubleedgedswordagainstcovid19
AT bianchifrans thepikfyveinhibitorapilimodadoubleedgedswordagainstcovid19
AT vandenbogaartgeert thepikfyveinhibitorapilimodadoubleedgedswordagainstcovid19
AT baranovmaksimv pikfyveinhibitorapilimodadoubleedgedswordagainstcovid19
AT bianchifrans pikfyveinhibitorapilimodadoubleedgedswordagainstcovid19
AT vandenbogaartgeert pikfyveinhibitorapilimodadoubleedgedswordagainstcovid19

Ejemplares similares